8-K current report · filed Aug 11, 2026

Aquestive Therapeutics, Inc. (AQST) 8-K Current Report: August 11, 2026

Item 7.01Item EX-99.1Item 2.02AQST overview

Short answer

Aquestive Therapeutics, Inc. (AQST) filed an 8-K current report with the SEC on August 11, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results for quarter ended June 30, 2026 announced on August 11, 2026.

Aquestive Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 results for quarter ended June 30, 2026 announced on August 11, 2026
  • Business update and detailed financial schedules available in Exhibit 99.1
  • Investor focus: operating performance and recent developments disclosed in the attached earnings release

Item 7.01 · Regulation FD Disclosure

  • Investor presentation disclosed under Reg FD for institutional investors, analysts and other market participants
  • Exhibit 99.2 contains the substantive investor messaging and may influence market expectations
  • Presentation available on Aquestive’s investor website, with future updates possible through subsequent disclosures

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $13.8M, up 38% from $10.0M, driven by higher manufacturing, supply, license, and royalty revenue
  • Anaphylm human-factors and PK studies completed; NDA resubmission remains targeted for Q3 2026 after January CRL
  • FDA expedited review will be requested, but approval timing remains uncertain and Anaphylm launch depends on regulatory clearance
  • Net loss $22.9M included an $11.7M one-time debt extinguishment loss; adjusted EBITDA loss improved to $5.2M from $9.3M
  • Cash $98.5M; 2026 guidance unchanged at $46–$50M revenue and $35–$30M adjusted EBITDA loss

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Aquestive Therapeutics, Inc. 8-K filings

Get the next AQST 8-K as it lands

Follow AQST for push alerts, or ask the research agent what this filing means.